U.S. markets open in 2 hours 49 minutes

Altimmune, Inc. (ALT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.64+0.76 (+5.90%)
At close: 04:00PM EST
13.63 -0.01 (-0.07%)
After hours: 07:53PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close12.88
Bid0.00 x 800
Ask0.00 x 900
Day's Range12.85 - 13.76
52 Week Range3.83 - 23.49
Avg. Volume1,464,691
Market Cap670.53M
Beta (5Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-2.39
Earnings DateMar 13, 2023 - Mar 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 20, 2017
1y Target Est29.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ALT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Altimmune, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    18 hours agoMorningstar
View more
  • GlobeNewswire

    Altimmune Appoints Raymond Jordt as Chief Business Officer

    Mr. Jordt brings over 25 years of industry experience in corporate strategy and business developmentGAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pha

  • GlobeNewswire

    Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

    GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune’s recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be

  • GlobeNewswire

    Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

    Greater than 75% relative reduction in liver fat content achieved at the 1.8 mg and 2.4 mg doses at 24 weeksSignificant reductions in serum alanine aminotransferase (ALT) and corrected T1 (cT1) observed, both established markers of liver inflammationMean weight loss of 7.2% (placebo adjusted 6.0%) in subjects without diabetes at the 1.8 mg doseGlycemic control maintained with trends toward improvements in fasting glucose and HbA1c in subjects with diabetesMeaningful reductions in blood pressure